Methodological Issues in Conducting Pilot Trials in Chronic Pain as Randomized, Double-blind, Placebo-controlled Studies

BACKGROUND

The efficacy of tapentadol extended release (ER) for managing chronic pain has been demonstrated in large-scale, randomized, controlled, phase 3 studies (N=318-1,030) in patients with chronic osteoarthritis (OA) pain, low back pain (LBP), and pain related to diabetic peripheral neuropathy (DPN), which led to registration in many regions, including the United States and Europe. 2 pilot 12-week, randomized, double-blind, placebo-controlled phase 2 studies of tapentadol ER for chronic pain (OA knee pain or LBP, n=91; DPN or peripheral herpetic neuralgia [PHN] pain; n=91) were conducted in Japan. These small exploratory studies were substantially underpowered compared with the registration trials.

METHODS

Patients in both studies were randomized (2:1) to tapentadol ER (25-250 mg) or placebo for 12 weeks (≤6-week titration plus maintenance periods).

RESULTS

For the primary efficacy endpoint (change in pain intensity from baseline to last week of treatment; last observation carried forward), both studies failed to differentiate between tapentadol ER and placebo; least-squares mean differences (95% confidence intervals) for tapentadol ER vs. placebo were -0.1 (-1.04, 0.80) in the OA/LBP study and -0.1 (-1.10, 0.99) in the DPN/PHN study. More than 80% of patients took concomitant analgesics during these studies. Tapentadol was well tolerated.

CONCLUSIONS

Both studies were associated with methodological issues, including populations with different disease entities, small sample sizes, use of concomitant analgesics, and possible placebo effect that may have led to the failure to differentiate between tapentadol ER and placebo.

Integration of borylation of aryllithiums and Suzuki–Miyaura coupling using monolithic Pd catalyst

Integration of the preparation of arylboronic esters and Suzuki–Miyaura coupling using monolithic Pd catalyst was successfully achieved.

Spatial and temporal distributions of (134)Cs and (137)Cs derived from the TEPCO Fukushima Daiichi Nuclear Power Plant accident in the North Pacific Ocean by using optimal interpolation analysis

Optimal interpolation (OI) analysis was used to investigate the oceanic distributions of (134)Cs and (137)Cs released from the Tokyo Electric Power Company Fukushima Daiichi Nuclear Power Plant (FNPP1) accident. From the end of March to early April 2011, extremely high activities were observed in the coastal surface seawater near the FNPP1. The high activities spread to a region near 165°E in the western North Pacific Ocean, with a latitudinal center of 40°N. Atmospheric deposition also caused high activities in the region between 180° and 130°W in the North Pacific Ocean. The inventory of FNPP1-released (134)Cs in the North Pacific Ocean was estimated to be 15.3 ± 2.6 PBq. About half of this activity (8.4 ± 2.6 PBq) was found in the coastal region near the FNPP1. After 6 April 2011, when major direct releases ceased, the FNPP1-released (134)Cs in the coastal region decreased exponentially with an apparent half-time of about 4.2 ± 0.5 days and declined to about 2 ± 0.4 PBq by the middle of May 2011. Taking into account that the (134)Cs/(137)Cs activity ratio was about 1 just after release and was extremely uniform during the first month after the accident, the amount of (137)Cs released by the FNPP1 accident increased the North Pacific inventory of (137)Cs due to bomb testing during the 1950s and early 1960s by 20%.

Switching between intermolecular and intramolecular reactions using flow microreactors: lithiation of 2-bromo-2′-silylbiphenyls

Switching between the intermolecular reaction and the intramolecular reaction was achieved at will using flow microreactors.

Perioperative management of severe anorexia nervosa

As the prevalence of anorexia nervosa (AN) increased, surgery in severe AN patients also increased in the 2000s. We experienced a surgical case of a patient with severe AN, showing an extremely low BMI of 8.6 kg m(-2). We investigated the problems associated with this case and propose criteria to manage severe AN. We endeavour to report on the perioperative management of rare and severe symptoms and surgical indications of severely malnourished patients. All published reports were identified through comprehensive searches using PubMed, BioMedLib, and the Japan Medical Abstracts Society with the following terms and keywords: 'anorexia nervosa', 'eating disorder', 'hypoglycaemia', 'leucocytopaenia', 'gelatinous bone marrow', 'surgery', and 'operation'. In cases of AN with a BMI under 13 kg m(-2), marked hypoglycaemia, leucocytopaenia <3.0×10(9) litre(-1), or both, potentially fatal complications frequently occur. Accordingly, patients need strict nutritional support to avoid re-feeding syndrome until surgery. During the course of anaesthesia, careless loading of glucose or catecholamine may lead to disturbance of electrolytes or fatal arrhythmia. Intensive care and early feeding as soon as possible after surgery are important to prevent surgical site infection. Although not many perioperative cases of AN have been reported, clinicians must be aware of the danger and the causes of mortality in critical cases. Thus, the decision to undertake surgery must be taken carefully and close perioperative coordination among physicians, surgeons, psychiatrists, anaesthesiologists, and intensivists is essential.